European Pre-Market Summary 10th November 2026: Earnings remain in focus, Ferrexpo stops production
ORIGINAL · NewsquawkEuropean Pre-Market Summary 10th November 2026: Earnings remain in focus, Ferrexpo stops productionRead originalHide original
Q3 Earnings Henkel (HEN3 GY): Revenue in-line. FY26 Organic Sales guidance midpoint beat. K+S (SDF GY): adj. EBITDA & Revenue beat. Narrows FY26 EBITDA guidance, due to supply-side constraints. Q4 Earnings Infineon (IFX GY): Revenue in-line, adj. EPS & Gross Margin higher Y/Y. Q1 Revenue guide miss. FY27 Revenue guide beat. Dividend increase. CEO: "expect a significant increase in revenue and profitability in fiscal year 2027" H1 Earnings Vodafone (VOD LN): Revenue beat, adj. EBITDAaL Organic Growth higher Y/Y. Upgrades FY27 adj. EBITDAaL and adj. FCF guidance. Pharmaceutical Roche (ROP SW): Updated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab demonstrating rapid amyloid removal dynamics and changes in key biomarkers. Bayer (BAYN GY): FDA has approved SUNHARBO (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with NIHSS or TIA. Reports/Updates BT (BT/A LN): Co. will not launch its partnership with SpaceX's (SPCX) Starlink, following on from the controversy surrounding signal failures in Ukraine, FT reports. Ferrexpo (FXPO LN): Following Ukrainian electricity damage, it has been decided to temporarily stop production.
The summary covered mixed earnings updates, Roche study data, Bayer’s FDA approval and Ferrexpo’s temporary production stop; available evidence adds Bayer trial and safety details.
News detail
Q3 Earnings Henkel (HEN3 GY): Revenue in-line. FY26 Organic Sales guidance midpoint beat. K+S (SDF GY): adj. EBITDA & Revenue beat. Narrows FY26 EBITDA guidance, due to supply-side constraints. Q4 Earnings Infineon (IFX GY): Revenue in-line, adj. EPS & Gross Margin higher Y/Y. Q1 Revenue guide miss. FY27 Revenue guide beat. Dividend increase. CEO: "expect a significant increase in revenue and profitability in fiscal year 2027" H1 Earnings Vodafone (VOD LN): Revenue beat, adj. EBITDAaL Organic Growth higher Y/Y. Upgrades FY27 adj. EBITDAaL and adj. FCF guidance. Pharmaceutical Roche (ROP SW): Updated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab demonstrating rapid amyloid removal dynamics and changes in key biomarkers. Bayer (BAYN GY): FDA has approved SUNHARBO (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with NIHSS or TIA. Reports/Updates BT (BT/A LN): Co. will not launch its partnership with SpaceX's (SPCX) Starlink, following on from the controversy surrounding signal failures in Ukraine, FT reports. Ferrexpo (FXPO LN): Following Ukrainian electricity damage, it has been decided to temporarily stop production.
Related stocks
2 stocks
What do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.